Australia · Delayed Price · Currency is AUD Opthea Earnings Call Transcripts
Fiscal Year 2025
-
The AGM covered director re-elections, adoption of the remuneration report, and approval of option grants, with all resolutions put to a poll and no questions raised by shareholders. Voting results will be published post-meeting.
-
Phase III trials failed to show efficacy for sozinibercept in wet AMD, leading to program termination and a settlement with investors that leaves the company with $20 million cash and no debt. A strategic review is underway to explore internal and external opportunities, with updates expected later this year.
-
Sozinibercept, a VEGF-C/D trap, is advancing through Phase 3 trials for wet AMD, targeting improved vision outcomes in combination with anti-VEGF-A agents. Pivotal data readouts are imminent, with strong market, payer, and physician support, and a potential FDA approval by late 2026.
-
Sozinibrecept is positioned as a first-in-class combination therapy for wet AMD, with pivotal phase 3 data expected in 2024 and potential FDA approval by end of 2026. The product targets a $7B+ U.S. market, offers robust clinical differentiation, and is supported by a strong commercial team and favorable payer feedback.
-
Sozinibercept, a first-in-class VEGF-C/D trap, has shown superior vision outcomes in wet AMD and is in two pivotal Phase III trials with top-line data expected in 2024. The company is well-funded, targeting a 2026 BLA submission, and preparing for a U.S. launch.
Fiscal Year 2024
-
Three late-stage ophthalmology assets are advancing toward commercialization, each with distinct mechanisms and market strategies. LENZ targets presbyopia with a daily eye drop, Aldeyra offers rapid relief for dry eye and allergy, and Opthea aims to improve wet AMD outcomes by blocking VEGF-C/D.
-
Sozinibercept, targeting VEGF-C/D, showed superior vision outcomes in phase II-B wet AMD trials when combined with standard care. Two pivotal phase III trials are fully enrolled, with top-line data expected in 2025, and commercial preparations underway.
-
Sozinibercept, a novel anti-VEGF-C/D, demonstrated superior vision outcomes in phase II-B and is advancing through two global phase III trials with readouts expected in 2025. The product targets a $10B market, has strong payer and physician interest, and benefits from a robust safety profile.
-
Sozinibercept, a first-in-class VEGF-C and -D trap, is in late-stage trials aiming to improve vision outcomes for wet AMD patients, with top-line data expected in 2025. The drug targets a $15B market and is positioned for use with any anti-VEGF-A therapy.
-
A novel therapy for wet AMD, sozinibercept, demonstrated superior vision outcomes in phase IIb trials and is advancing through two pivotal phase III studies, with top-line data expected in 2025. The drug targets unmet needs in a $15B+ market and is positioned for broad combination use.
-
Sozinibercept is positioned as a first-in-class add-on therapy for wet AMD, showing superior vision gains in phase IIb trials and targeting broad use with existing anti-VEGF-A drugs. Two pivotal phase 3 trials are fully enrolled, with top-line data expected mid-next year.